Form 4: Xeris Biopharma Director Dawn Halkuff Receives Significant Restricted Stock Unit Award

Xeris Biopharma Holdings, Inc. Director Dawn Halkuff was awarded 50,000 restricted stock units, aligning her interests with shareholders and increasing her beneficial ownership.

Summary

• Dawn Halkuff, a Director at Xeris Biopharma Holdings, Inc. (XERS), was granted 50,000 restricted stock units (RSUs) on June 4, 2025.
• These RSUs were awarded under the Company's 2018 Stock Option and Incentive Plan at a price of $0 per unit, indicating an equity award.
• Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
• The 50,000 RSUs are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.
• Following this transaction, Dawn Halkuff directly beneficially owns 157,500 shares of common stock.
• Additionally, she indirectly beneficially owns 5,410 shares through the DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017, bringing her total beneficial ownership to 162,910 shares.

Sentiment

Score: 7

Explanation: The filing indicates an equity award to a director, which generally aligns management interests with shareholders and is a positive signal of commitment, though it's a routine compensation event.

Positives

• The award of 50,000 restricted stock units to Director Dawn Halkuff aligns her long-term financial interests directly with those of the company's shareholders, as the value of the award is contingent on the company's stock performance.
• The increase in Director Halkuff's beneficial ownership demonstrates continued commitment and confidence in Xeris Biopharma's future prospects.

Negatives

• No negative information is directly presented in this Form 4 filing, as it primarily reports a routine equity award.

Future Outlook

The 50,000 restricted stock units awarded to Director Dawn Halkuff are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders, indicating a future increase in her direct shareholdings and continued alignment with company performance.

Industry Context

This Form 4 filing reports an individual insider transaction, specifically a restricted stock unit award to a director, which is a common form of executive and director compensation in the biopharmaceutical industry aimed at aligning management incentives with shareholder interests. It does not provide broader industry trend analysis.

Related Party Transactions

• The acquisition of 50,000 restricted stock units by Director Dawn Halkuff from Xeris Biopharma Holdings, Inc. constitutes a related party transaction, as it involves a transaction between the company and a member of its board of directors. This is a standard compensation award under the company's existing incentive plan.

Stakeholder Impact

• Shareholders: The award of restricted stock units to a director aligns management's long-term interests with shareholder value, as the value of the award is tied to the company's stock performance.
• Employees: While not directly impacting all employees, such compensation practices can set precedents for equity-based incentives within the company.

Next Steps

• Vesting of the 50,000 restricted stock units on the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Key Dates

Keywords

Xeris Biopharma Holdings Inc, XERS, SEC Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Award, Beneficial Ownership, Biopharma